Lilly to CMS: Failure to cover Amyvid will chill Alzheimer's R&D
This article was originally published in Scrip
Executive Summary
After a long road to approval for its non-therapeutic radiopharmaceutical Amyvid (florbetapir F 18 injection), the issue Lilly has been grappling with over the past year – Medicare reimbursement – is a perfect example of how getting a product across the FDA finish line is never the last hurdle in reaching success.